We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
- Authors
Fisher, B; Dignam, J; Bryant, J; DeCillis, A; Wickerham, D L; Wolmark, N; Costantino, J; Redmond, C; Fisher, E R; Bowman, D M; Deschênes, L; Dimitrov, N V; Margolese, R G; Robidoux, A; Shibata, H; Terz, J; Paterson, A H; Feldman, M I; Farrar, W; Evans, J; Lickley, H L
- Abstract
In 1982, the National Surgical Adjuvant Breast and Bowel Project initiated a randomized, double-blinded, placebo-controlled trial (B-14) to determine the effectiveness of adjuvant tamoxifen therapy in patients with primary operable breast cancer who had estrogen receptor-positive tumors and no axillary lymph node involvement. The findings indicated that tamoxifen therapy provided substantial benefit to patients with early stage disease. However, questions arose about how long the observed benefit would persist, about the duration of therapy necessary to maintain maximum benefit, and about the nature and severity of adverse effects from prolonged treatment.
- Publication
Journal of the National Cancer Institute, 1996, Vol 88, Issue 21, p1529
- ISSN
0027-8874
- Publication type
Journal Article
- DOI
10.1093/jnci/88.21.1529